Limits...
Cisplatin-based chemotherapy versus cetuximab in concurrent chemoradiotherapy for locally advanced head and neck cancer treatment.

Hu MH, Wang LW, Lu HJ, Chu PY, Tai SK, Lee TL, Chen MH, Yang MH, Chang PM - Biomed Res Int (2014)

Bottom Line: Hematologic side effects were significantly more frequent in the SD-CCRT than in the BioRT group.Mucositis frequency was similar.Both groups showed good compliance.

View Article: PubMed Central - PubMed

Affiliation: Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan ; Faculty of Medicine, National Yang Ming University, No. 155, Section 2, Linong Street, Taipei 112, Taiwan ; Division of Hematology and Oncology, Department of Medicine, Cardinal Tien Hospital, No. 362, Zhongzheng Road, New Taipei City 231, Taiwan.

ABSTRACT

Background and purpose: This study aimed to analyze survival, clinical responses, compliance, and adverse effects in locally advanced head and neck cancer (LAHNC) patients treated with split-dose cisplatin-based concurrent chemoradiation therapy (SD-CCRT) or cetuximab with concurrent radiation therapy (BioRT).

Materials and methods: We retrospectively evaluated 170 LAHNC patients diagnosed between January 1, 2009, and July 31, 2012: 116 received CCRT and 54 received BioRT.

Results: Complete response rates were similar in the SD-CCRT and BioRT groups (63.8% versus 59.3%; P = 0.807), and locoregional relapse rates were 18.1% and 13.0%, respectively (P = 0.400). The 3-year relapse-free survival rate was 65.8% in the SD-CCRT group and 65.5% in the BioRT group, respectively (P = 0.647). The 3-year overall survival rate was 78.5% in the SD-CCRT group and 70.9% in the BioRT group, respectively (P = 0.879). Hematologic side effects were significantly more frequent in the SD-CCRT than in the BioRT group. Mucositis frequency was similar.

Conclusions: Primary SD-CCRT and BioRT both showed good clinical response and survival. Hematologic toxicities were more frequent, but tolerable, in the SD-CCRT group. Both groups showed good compliance.

Show MeSH

Related in: MedlinePlus

3-year relapse-free survival between BioRT and SD-CCRT group. 3-year RFS is 65.8% in SD-CCRT group versus 65.5% in BioRT group (P = 0.647).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4109223&req=5

fig1: 3-year relapse-free survival between BioRT and SD-CCRT group. 3-year RFS is 65.8% in SD-CCRT group versus 65.5% in BioRT group (P = 0.647).

Mentions: The complete response rate was similar in the SD-CCRT and BioRT groups (63.8% versus 59.3%; P = 0.807). After a median follow-up of 22.5 months, locoregional relapse was noted in 18.1% of patients in the SD-CCRT group and in 13.0% of patients in the BioRT group (P = 0.400), whereas distant metastasis was noted in 6.9% of patients in the SD-CCRT group and 3.7% of patients in the BioRT group (P = 0.410) (Table 4). The 3-year relapse-free survival rate was 65.8% in the SD-CCRT group and 65.5% in the BioRT group (P = 0.647; Figure 1). The 3-year overall survival rate was 78.5% in the SD-CCRT group and 70.9% in the BioRT group (P = 0.879; Figure 2).


Cisplatin-based chemotherapy versus cetuximab in concurrent chemoradiotherapy for locally advanced head and neck cancer treatment.

Hu MH, Wang LW, Lu HJ, Chu PY, Tai SK, Lee TL, Chen MH, Yang MH, Chang PM - Biomed Res Int (2014)

3-year relapse-free survival between BioRT and SD-CCRT group. 3-year RFS is 65.8% in SD-CCRT group versus 65.5% in BioRT group (P = 0.647).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4109223&req=5

fig1: 3-year relapse-free survival between BioRT and SD-CCRT group. 3-year RFS is 65.8% in SD-CCRT group versus 65.5% in BioRT group (P = 0.647).
Mentions: The complete response rate was similar in the SD-CCRT and BioRT groups (63.8% versus 59.3%; P = 0.807). After a median follow-up of 22.5 months, locoregional relapse was noted in 18.1% of patients in the SD-CCRT group and in 13.0% of patients in the BioRT group (P = 0.400), whereas distant metastasis was noted in 6.9% of patients in the SD-CCRT group and 3.7% of patients in the BioRT group (P = 0.410) (Table 4). The 3-year relapse-free survival rate was 65.8% in the SD-CCRT group and 65.5% in the BioRT group (P = 0.647; Figure 1). The 3-year overall survival rate was 78.5% in the SD-CCRT group and 70.9% in the BioRT group (P = 0.879; Figure 2).

Bottom Line: Hematologic side effects were significantly more frequent in the SD-CCRT than in the BioRT group.Mucositis frequency was similar.Both groups showed good compliance.

View Article: PubMed Central - PubMed

Affiliation: Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan ; Faculty of Medicine, National Yang Ming University, No. 155, Section 2, Linong Street, Taipei 112, Taiwan ; Division of Hematology and Oncology, Department of Medicine, Cardinal Tien Hospital, No. 362, Zhongzheng Road, New Taipei City 231, Taiwan.

ABSTRACT

Background and purpose: This study aimed to analyze survival, clinical responses, compliance, and adverse effects in locally advanced head and neck cancer (LAHNC) patients treated with split-dose cisplatin-based concurrent chemoradiation therapy (SD-CCRT) or cetuximab with concurrent radiation therapy (BioRT).

Materials and methods: We retrospectively evaluated 170 LAHNC patients diagnosed between January 1, 2009, and July 31, 2012: 116 received CCRT and 54 received BioRT.

Results: Complete response rates were similar in the SD-CCRT and BioRT groups (63.8% versus 59.3%; P = 0.807), and locoregional relapse rates were 18.1% and 13.0%, respectively (P = 0.400). The 3-year relapse-free survival rate was 65.8% in the SD-CCRT group and 65.5% in the BioRT group, respectively (P = 0.647). The 3-year overall survival rate was 78.5% in the SD-CCRT group and 70.9% in the BioRT group, respectively (P = 0.879). Hematologic side effects were significantly more frequent in the SD-CCRT than in the BioRT group. Mucositis frequency was similar.

Conclusions: Primary SD-CCRT and BioRT both showed good clinical response and survival. Hematologic toxicities were more frequent, but tolerable, in the SD-CCRT group. Both groups showed good compliance.

Show MeSH
Related in: MedlinePlus